AstraZeneca localized in Russia production of ticagrelor
Company AstraZeneca localized at its own plant in Kaluga region manufacture of the finished dosage form of ticagrelor 90 mg for the treatment of patients with acute coronary syndrome (ACS).
Ticagrelor (trade name of Brilinta) is included in the list of essential drugs and included in the standards of specialized medical care for patients with acute myocardial infarction (with ST-segment elevation) and unstable angina, acute and recurrent myocardial infarction (without ST-segment elevation). Localization of production of the drug is responsible for several strategic challenges facing the national system of health: contributing to the implementation of state plans for import substitution in the fight against cardiovascular disease and enhances patient access to effective treatment.
According to the state program “Development of pharmaceutical and medical industry”, adopted in 2009, 2020, 9 out of 10 packages of vital and essential medicinal products at the Russian market must be produced, and the localization of production accelerates the achievement of this goal.
